ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

ClinicalTrials.gov ID: NCT06420297

Public ClinicalTrials.gov record NCT06420297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Study identification

NCT ID
NCT06420297
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Enrollment
160 participants

Conditions and interventions

Interventions

  • Carbetocin Drug

Drug

Eligibility (public fields only)

Age range
5 Years to 30 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 10, 2024
Primary completion
Apr 30, 2029
Completion
May 31, 2029
Last update posted
Dec 2, 2025

2024 – 2029

United States locations

U.S. sites
19
U.S. states
15
U.S. cities
19
Facility City State ZIP Site status
Children's of Alabama Birmingham Alabama 35233
Phoenix Children's Hospital Phoenix Arizona 85006
University of California Irvine Orange California 92697
Stanford University School of Medicine Palo Alto California 94304
Rady Children's Hospital San Diego San Diego California 92123
Children's Hospital Colorado Aurora Colorado 80045
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611
University of Iowa Iowa City Iowa 52242
Boston Children's Hospital Boston Massachusetts 02115
Children's Mercy Kansas City Kansas City Missouri 64108
SSM Health/Saint Louis University St Louis Missouri 63104
Maimonides Medical Center Brooklyn New York 11219
Nationwide Children's Hospital Columbus Ohio 43205
UPMC-Children's Hospital Pittsburgh Pittsburgh Pennsylvania 15224
Vanderbilt Clinical Research Center Nashville Tennessee 37232
Cook Children's Health Care System Fort Worth Texas 79104
Christus Children's San Antonio Texas 78207
University of Utah Salt Lake City Utah 84108
Seattle Children's Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06420297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 2, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06420297 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →